Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (81-90 of 367) with videos related to

Pageof 37
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief reportEgbert F Smit, Anne-Marie C Dingemans, Frederik B Thunnissen, et al.
Oncoimmunology|May 1, 2023
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodesFrank J Borm, Jasper Smit, Joyce Bakker, et al.
Targeted Oncology|December 11, 2021
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical PracticeLishi Lin, Egbert F Smit, Adrianus J de Langen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 23, 2011
Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancerFrank J Lagerwaard, Naomi E Verstegen, Cornelis J A Haasbeek, et al.
Therapeutic Drug Monitoring|June 22, 2023
Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC PatientsLishi Lin, Hannerieke J Barkman, Egbert F Smit, et al.
Case Reports in Oncology|April 8, 2014
Benefit of a second opinion for lung cancer: no metastasis to the kidney but a synchronous primary renal neoplasmMarleen J Ter Avest, Romane M Schook, Lyan G Koudstaal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?Wieneke A Buikhuisen, Jacobus A Burgers, Andrew D Vincent, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 4, 2004
The performance of( 18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodulesGerarda J Herder, Richard P Golding, Otto S Hoekstra, et al.
Journal of Medical Internet Research|February 6, 2014
Why do patients and caregivers seek answers from the Internet and online lung specialists? A qualitative studyRomane Milia Schook, Cilia Linssen, Franz Mnh Schramel, et al.
Chest|October 21, 2005
Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomographyGerarda J Herder, Harm van Tinteren, Richard P Golding, et al.
Pageof 37

Showing results (81-90 of 367) with videos related to

Sort By:
Pageof 37
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief reportEgbert F Smit, Anne-Marie C Dingemans, Frederik B Thunnissen, et al.
Oncoimmunology|May 1, 2023
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodesFrank J Borm, Jasper Smit, Joyce Bakker, et al.
Targeted Oncology|December 11, 2021
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical PracticeLishi Lin, Egbert F Smit, Adrianus J de Langen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 23, 2011
Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancerFrank J Lagerwaard, Naomi E Verstegen, Cornelis J A Haasbeek, et al.
Therapeutic Drug Monitoring|June 22, 2023
Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC PatientsLishi Lin, Hannerieke J Barkman, Egbert F Smit, et al.
Case Reports in Oncology|April 8, 2014
Benefit of a second opinion for lung cancer: no metastasis to the kidney but a synchronous primary renal neoplasmMarleen J Ter Avest, Romane M Schook, Lyan G Koudstaal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?Wieneke A Buikhuisen, Jacobus A Burgers, Andrew D Vincent, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 4, 2004
The performance of( 18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodulesGerarda J Herder, Richard P Golding, Otto S Hoekstra, et al.
Journal of Medical Internet Research|February 6, 2014
Why do patients and caregivers seek answers from the Internet and online lung specialists? A qualitative studyRomane Milia Schook, Cilia Linssen, Franz Mnh Schramel, et al.
Chest|October 21, 2005
Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomographyGerarda J Herder, Harm van Tinteren, Richard P Golding, et al.
Pageof 37